

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>lomitapide</b>
Brand Name	Juxtapid™
Dosage Form(s)	5 mg, 10 mg, and 20 mg capsules
Manufacturer	Aegerion Pharmaceuticals (Canada) Ltd.
<b>Submission Review</b>	<b>New Submission</b>
Use Reviewed	Lomitapide is used to reduce very high cholesterol caused by a condition that runs in families called homozygous familial hypercholesterolemia or HoFH.
Common Drug Review (CDR)	Yes. CDR recommended: <b>Do not list</b> . Visit the CDR website for more details: <a href="https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0386_Juxtapid-Apr-21_15.pdf">https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0386_Juxtapid-Apr-21_15.pdf</a>
Drug Benefit Council (DBC)	Lomitapide was not reviewed by the DBC
<b>Drug Coverage Decision</b>	<b>Non-Benefit</b>
Date	June 23, 2015
Reason(s)	Lomitapide was not reviewed by the DBC because it received a “Do not list” recommendation from the CDR. The Ministry of Health reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, the Final Canadian Drug Expert Committee (CDEC) Recommendation and Reasons, Clinical Practice Reviews from two specialists and public input collected through Ministry public input mechanism, Your Voice. <ul style="list-style-type: none"> <li>• Lomitapide demonstrated some advantage over placebo (no drug) with respect to efficacy as there was a percent decline from baseline in bad cholesterol (LDL-C) in these patients. But there was no evidence provided to evaluate the cardiovascular benefit of lomitapide.</li> <li>• Lomitapide was associated with significant hepatic adverse events. As lomitapide is indicated for long-term use, the clinical relevance of the observed increase in hepatic fat, including the risk of progression to steatohepatitis and cirrhosis, requires further evaluation.</li> <li>• Based on economic considerations and the submitted product price, the drug was not cost effective and did not offer optimal value for money.</li> </ul>
Other Information	Not applicable

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.